2024
A comparison of chemiluminescent immunoassay and enzyme-linked immunosorbent assay for detecting phospholipase A2 receptor antibody in primary membranous nephropathy
Ma X, Wang R, Wei L, Liu P, Jing L, Wang J, Dong W, Tian X, Fu R. A comparison of chemiluminescent immunoassay and enzyme-linked immunosorbent assay for detecting phospholipase A2 receptor antibody in primary membranous nephropathy. Practical Laboratory Medicine 2024, 39: e00385. PMID: 38495349, PMCID: PMC10940994, DOI: 10.1016/j.plabm.2024.e00385.Peer-Reviewed Original ResearchAnti-PLA2R antibodiesEnzyme-linked immunosorbent assayNegative predictive valuePositive predictive valueAnti-PLA2RMembranous nephropathyChemiluminescence immunoassayLevels of anti-PLA2R antibodiesPhospholipase A2 receptor antibodyPredictive valuePrimary membranous nephropathyPhospholipase A2 receptorImmunosorbent assayResults Serum levelsStatistical analysis of sensitivityROC curve analysisNon-membranous nephropathyStatistically significant differencePMN groupReceptor antibodiesSerum levelsA2 receptorsSpearman correlation analysisDiagnostic valueNephropathy
2023
IgG4-Related Disease with IgG1-Dominant Membranous Nephropathy: A Rare Case Report
Duan Y, Qu Y, Zhuang J, Abudula R, Zhang C, Tian X, Jiang H. IgG4-Related Disease with IgG1-Dominant Membranous Nephropathy: A Rare Case Report. Integrative Medicine In Nephrology And Andrology 2023, 10: e00007. DOI: 10.1097/imna-d-23-00007.Peer-Reviewed Case Reports and Technical NotesMembranous nephropathyClinical remissionIgG4-RDNephrotic syndromeIgG4-related tubulointerstitial nephritisRare pathological featureComplete clinical remissionPrimary membranous nephropathyRare case reportGlucocorticoid therapyPLA2R stainingKidney involvementMaintenance therapyRituximab treatmentRTX treatmentImmunoglobulin G4Tubulointerstitial nephritisKidney biopsySubepithelial depositionPathological featuresCase reportFibroinflammatory disorderAntigen stainingNephropathyReceptor antigenCombination Therapy of Low-dose Steroids, Tacrolimus and Mycophenolate Mofetil in Primary Membranous Nephropathy: A Single-center Retrospective Cohort Study
Zhao S, Jia L, Cui C, Chen Z, Duan Z, Gao J, Wei L, Xue X, Lei F, Yang Y, Liu J, Xu P, Wang R, Wei Y, Tian X, Fu R. Combination Therapy of Low-dose Steroids, Tacrolimus and Mycophenolate Mofetil in Primary Membranous Nephropathy: A Single-center Retrospective Cohort Study. Integrative Medicine In Nephrology And Andrology 2023, 10: e00012. DOI: 10.1097/imna-d-22-00012.Peer-Reviewed Original ResearchPrimary membranous nephropathyIntravenous cyclophosphamideRegimen groupMycophenolate mofetilMembranous nephropathyNephrotic syndromeCombination therapyBiopsy-proven primary membranous nephropathySingle-center retrospective cohort studyPC groupCumulative complete remission ratesLow-dose glucocorticoidsLow-dose steroidsNon-inferior efficacyRetrospective cohort studySerum creatinine levelsComplete remission rateCommon pathological typeUrinary protein levelsFavorable safety profileBest combination therapyAlternative treatment choiceRemission rateAdverse eventsCohort studyThe Combination Therapy of Glucocorticoids, Tacrolimus, and Mycophenolate Mofetil in Primary Membranous Nephropathy Coexisting with Type 2 Diabetes Mellitus: A Retrospective Study
Wang Y, Cui C, Tian X, Wang L, Ma X, Ge H, Zhang L, Xue X, Chen Z, Huo Y, Wang H, Fu R, Jia L. The Combination Therapy of Glucocorticoids, Tacrolimus, and Mycophenolate Mofetil in Primary Membranous Nephropathy Coexisting with Type 2 Diabetes Mellitus: A Retrospective Study. Integrative Medicine In Nephrology And Andrology 2023, 10: e00010. DOI: 10.1097/imna-d-22-00010.Peer-Reviewed Original ResearchPrimary membranous nephropathyMycophenolate mofetilCTX groupMembranous nephropathyType 2 diabetes mellitusCombination of glucocorticoidsSerum albumin levelUrinary protein excretionData of patientsLong-term efficacyWorse glycemic controlCTX regimenProteinuria reductionCyclophosphamide regimenAlbumin levelsDiabetes mellitusGlycemic controlImmunosuppressive agentsProtein excretionRetrospective studyCombination therapyBlood glucoseType 2Disease severityGlucocorticoids